

REMARKS

The Final Office Action mailed July 3, 2002 (hereinafter the Office Action), has been received and reviewed. Claims 1 through 52 are currently pending in the application, and claims 1 through 52 stand rejected. However, Applicants herein cancel claims 2 and 5 through 52 without prejudice or disclaimer, and Applicants have herein amended claims 1, 3 and 4. Applicants, therefore, respectfully request reconsideration of the application in light of the amendments and remarks set forth herein.

Claim Objections

Claims 18 and 36 are objected to in the Office Action due to the apparent misspelling of the term "interleukin," which is included in the claims. Applicants respectfully note, however, that claims 18 and 36 are cancelled herein without prejudice or disclaimer, and applicants respectfully request that the objection to these claims be withdrawn.

35 U.S.C. § 112 Rejections

Claims 39 through 52 are rejected in the Office Action under 35 U.S.C. § 112, first paragraph. Applicants respectfully note, however, that claims 39 through 52 are cancelled herein without prejudice or disclaimer, and Applicants respectfully request that the rejection of these claims under Section 112, first paragraph, be withdrawn.

Claims 1 through 52 are rejected in the Office Action under 35 U.S.C. § 112, second paragraph. With regard to these claims, it is asserted in the Office Action that the term "substantially" renders the terms "in-situ aggregation effect" and "improved bioavailability" indefinite. Applicants respectfully note, however, that claims 1, 3 and 4 as they are amended do not include the terms "substantially," "in-situ aggregation effect" or "improved bioavailability," and Applicants respectfully request that the rejection of claims 1, 3, and 4 under Section 112, second paragraph be withdrawn.